Details of the Drug Reposition

General Information of This Drug (ID: DMVJXOH)

Drug Name
BMS-986012   DMVJXOH
Drug Type
Antibody

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
2 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Solid tumour/cancer DISZR48F 2A00-2F9Z Phase 2 [1]
Small-cell lung cancer DISK3LZD 2C25.Y Phase 2 [2]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT04702880) A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer. U.S. National Institutes of Health.
2 ClinicalTrials.gov (NCT04702880) A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer. U.S. National Institutes of Health.